Holmes Biopharma, Inc.

Holmes Biopharma, Inc.

September 05, 2007 13:39 ET

Holmes Biopharma Omaha Phase 1 Clinic Expansion

SCOTTSDALE, ARIZONA--(Marketwire - Sept. 5, 2007) - Holmes Biopharma, Inc. (PINK SHEETS:HLMB) announces the expansion and occupancy of our Omaha Phase 1 facility. Due to the continuous rise in sales we have added an additional 10,000 square feet of clinic space, greatly increasing our bed capacity. This now brings the total square footage to 33,000. "Our expansion enables us to keep up with our continuous growth and it translates into increased revenue and greater profitability," stated Dr. Sohail Khattak, President & CEO Qualia Clinical Service.

About Holmes:

Holmes Biopharma Inc. and it's wholly owned subsidiary, Qualia Clinical Service, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products rapidly from laboratory to the market. Holmes is also actively involved in developing new drugs and drug delivery systems. Currently, clinics operate in Omaha, Nebraska USA, Toronto, Canada. and Kiev, Ukraine, Eastern Europe. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information